A study published in the journal Frontiers of Medicine has found an association between the inactivated COVID-19 vaccine CoronaVac from Sinovac Biotech and immune thrombotic thrombocytopenic purpura ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports ...

Realities of a 'new frontier' of conflict and changing battlefields have forced the Philippines to retool its defence ...

This report presents two cases of TTP occurring after the administration of the inactivated vaccine CoronaVac from Sinovac ...

Tetanus is a serious bacterial infection caused by Clostridium tetani, which affects the nervous system, leading to muscle stiffness and spasms. With an increased awareness of disease prevention, ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...

In 2021, Kennedy told The Associated Press that a similar claim was “misinformation,” and while he was a part of more than 30 lawsuits about vaccine safety, none had appeared before the ...

Although getting a vaccine might be terrifying to some, staying up-to-date and getting them each year greatly decreases your risk of contracting and spreading diseases. But it's important to note ...

Or sign-in if you have an account. An mRNA vaccine, a cousin to the COVID vaccines that blunted the pandemic, has entered human trials as a treatment for lung cancer. BNT116 is a striking example ...

About a week later, the agency authorized an updated version of Novavax’s protein subunit vaccine for people 12 years and older. The mRNA vaccines specifically target KP.2, a subvariant of JN.